|
|
Blood, 1 November 2007, Vol. 110, No. 9, pp. 3102-3111.
Prepublished online as a Blood First Edition Paper on July 26, 2007; DOI 10.1182/blood-2007-05-075176.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLE
Lymphoma dissemination: the other face of lymphocyte homing
Steven T. Pals1,
David J. J. de Gorter1, and
Marcel Spaargaren1
1 Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
The orchestration of systemic immune responses is critically dependent on coordinated lymphocyte migration and recirculation. This "homing" guides lymphocytes to the microenvironments that control their differentiation and survival, disperses the immunologic repertoire, and targets effector lymphocytes to sites of antigenic insult. Lymphocyte homing is a multistep process that requires chemotaxis and cell adhesion coupled with strategies to overcome physical barriers. At the molecular level, it is regulated by adhesion molecules and chemokines, and facilitated by intrinsic molecular programs that allow "ameboid" shape change, allowing highly effective lymphocyte traffic between different tissue compartments. In case of malignant transformation, however, the fact that lymphocytes are "licensed to move" forms a serious threat to the organism, because it permits rapid tumor dissemination irrespective of the conventional anatomic boundaries limiting early spread in most types of cancer. Thus, unlike the metastatic spread of other cancers, lymphoma dissemination generally is not a reflection of tumor progression but of conserved physiological behavior. The dissemination patterns often reflect basic rules of lymphocyte homing, explaining the strikingly tissue-specific dissemination of, for example, mucosal lymphomas, cutaneous lymphomas, and multiple myeloma. Understanding the molecular mechanisms underlying this behavior may provide novel targets for treatment of lymphoma patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Ravoet, C. Sibille, C. Gu, M. Libin, B. Haibe-Kains, C. Sotiriou, M. Goldman, F. Roufosse, and K. Willard-Gallo
Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways
Blood,
October 1, 2009;
114(14):
2969 - 2983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Bernstein, J. M. Unger, M. LeBlanc, J. Friedberg, T. P. Miller, and R. I. Fisher
Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group
J. Clin. Oncol.,
January 1, 2009;
27(1):
114 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, H. Fang, Q.-F. Liu, J. Lu, S.-N. Qi, H. Wang, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, et al.
Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring
Blood,
October 15, 2008;
112(8):
3057 - 3064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells
Blood,
April 1, 2008;
111(7):
3364 - 3372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Bierman, M. L. Villanueva, and J. O. Armitage
Diffuse large B-cell lymphoma of the breast: a distinct entity?
Ann. Onc.,
February 1, 2008;
19(2):
201 - 202.
[Full Text]
[PDF]
|
|
|
|
|
